

BUPROPION- bupropion tablet, extended release
Zydus Lifesciences Limited

BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (XL)

Manufactured by:
Cadila Healthcare Ltd.
India.

SPL MEDGUIDE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 65841-780-05

Bupropion Hydrochloride Extended-release Tablets USP (XL), 300 mg
500 Tablets
Rx only

NDC 65841-780-05

ONCE-DAILY

buPROPion
Hydrochloride
Extended-Release
Tablets, USP (XL)

300 mg

WARNING: Do not use in combination with Zyban® or any other medicines that contain bupropion hydrochloride.

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

zydus

500 Tablets
Rx only

Each extended-release tablet contains 300 mg of buPROPion hydrochloride USP

Usual Dosage: Take one tablet daily or as directed by physician. See package insert for complete prescribing information.

Store at 20° to 25°C (68° to 77°F)
[See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP.

Keep this and all drugs out of the reach of children.

Zyban® is the registered trade mark of GlaxoSmithKline.

Manufactured by:
Zydus Lifesciences Ltd.
Ahmedabad, India

Rev.: 08/22

NDC 65841-836-05

Bupropion Hydrochloride Extended-release Tablets USP (XL), 150 mg
500 Tablets
Rx only

NDC 65841-836-05

ONCE-DAILY

**buPROPion
Hydrochloride
Extended-Release
Tablets, USP (XL)**

150 mg

WARNING: Do not use in combination with Zyban® or any other medicines that contain bupropion hydrochloride.

PHARMACIST: Dispense the Medication Guide provided separately to each patient

zydus

**500 Tablets
Rx only**

Manufactured by:
Zydus Lifesciences Ltd.
Ahmedabad, India

Each extended-release tablet contains 150 mg of buPROPion hydrochloride USP

Usual Dosage: Take one tablet daily or as directed by physician. See package insert for complete prescribing information.

Store at 20° to 25°C (68° to 77°F)
[See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP.

Keep this and all drugs out of the reach of children.

Zyban® is the registered trade mark of GlaxoSmithKline.

Rev.: 08/22

BUPROPION

bupropion tablet, extended release

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:65841-780
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BUPROPION HYDROCHLORIDE (UNII: ZG7E5POY8O) (BUPROPION - UNII:01ZG3TPX31)	BUPROPION HYDROCHLORIDE	300 mg

Inactive Ingredients

Ingredient Name	Strength
HYPROMELLOSES (UNII: 3NXW29V3WO)	
MAGNESIUM STEARATE (UNII: 70097M6I3O)	
METHACRYLIC ACID (UNII: 1CS02G8656)	
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)	
POVIDONE (UNII: FZ989GH94E)	
ETHYLCELLULOSES (UNII: 7Z8S9VYZ4B)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
BUTYL ALCOHOL (UNII: 8PJ61P6TS3)	

FERROSO FERRIC OXIDE (UNII: XM0M87F357)

ISOPROPYL ALCOHOL (UNII: ND2M416302)

PROPYLENE GLYCOL (UNII: 6DC9Q167V3)

SHELLAC (UNII: 46N107B710)

AMMONIA (UNII: 5138Q19F1X)

Product Characteristics

Color	YELLOW (CREAMY WHITE TO PALE YELLOW)	Score	no score
Shape	ROUND (ROUND)	Size	9mm
Flavor		Imprint Code	354
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:65841-780-06	30 in 1 BOTTLE; Type 0: Not a Combination Product	02/15/2014	
2	NDC:65841-780-16	90 in 1 BOTTLE; Type 0: Not a Combination Product	02/15/2014	
3	NDC:65841-780-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	02/15/2014	
4	NDC:65841-780-10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	02/15/2014	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA201567	02/15/2014	

BUPROPION

bupropion tablet, extended release

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:65841-836
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BUPROPION HYDROCHLORIDE (UNII: ZG7E5POY8O) (BUPROPION - UNII:01ZG3TPX31)	BUPROPION HYDROCHLORIDE	150 mg

Inactive Ingredients

Ingredient Name	Strength
HYPROMELLOSES (UNII: 3NXW29V3WO)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
METHACRYLIC ACID (UNII: 1CS02G8656)	
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)	
POVIDONE (UNII: FZ989GH94E)	
ETHYLCELLULOSES (UNII: 7Z8S9VYZ4B)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
BUTYL ALCOHOL (UNII: 8PJ61P6TS3)	
FERROSO FERRIC OXIDE (UNII: XM0M87F357)	
ISOPROPYL ALCOHOL (UNII: ND2M416302)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
SHELLAC (UNII: 46N107B71O)	
AMMONIA (UNII: 5138Q19F1X)	

Product Characteristics

Color	YELLOW (CREAMY WHITE TO PALE YELLOW)	Score	no score
Shape	ROUND (ROUND)	Size	8mm
Flavor		Imprint Code	353
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:65841-836-06	30 in 1 BOTTLE; Type 0: Not a Combination Product	08/02/2018	
2	NDC:65841-836-16	90 in 1 BOTTLE; Type 0: Not a Combination Product	08/02/2018	
3	NDC:65841-836-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	08/02/2018	
4	NDC:65841-836-10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	08/02/2018	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA201567	08/02/2018	

Labeler - Zydus Lifesciences Limited (918596198)

Registrant - Zydus Lifesciences Limited (918596198)

Establishment

Name	Address	ID/FEI	Business Operations
------	---------	--------	---------------------

Zydus Lifesciences
Limited

918596198

ANALYSIS(65841-780, 65841-836) , MANUFACTURE(65841-780, 65841-836)

Revised: 11/2024

Zydus Lifesciences Limited